查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553460

局部麻醉剂市场规模、份额、趋势分析报告：按药物、按应用、按地区、细分市场预测，2024-2030

Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

局部麻醉剂市场成长与趋势：

2030年，全球局部麻醉剂市场规模预计将达到51.4亿美元，预计2024年至2030年复合年增长率为3.6%。

世界各地的外科手术数量不断增加，包括整容手术、牙科和整形手术，正在推动局部麻醉剂的成长。

需要术后镇痛的外科手术数量大幅增加，预计这一趋势将在整个预测期内持续下去。约 65.0% 的外科手术需要术后疼痛管理。这可能会推动对局部麻醉剂的需求。

Bupivacaine、Articaine、Ropivacaine等有效新药的推出也推动了全球局部麻醉剂市场的成长。新兴国家不断上涨的医疗费用预计将导致印度、中国和巴西等国家的手术数量增加。预计这将有助于该地区的市场成长。

局部麻醉剂市场报告亮点

  • 截至 2016 年，Lidocaine在产品市场上占据主导地位，因为它被广泛用作局部麻醉剂和注射麻醉剂。
  • 依应用，市场分为注射麻醉剂和局部麻醉剂。由于局部麻醉剂广泛应用于各种外科手术，预计在预测期内局部麻醉剂市场将由注射剂市场主导。在预测期内，药物传递系统的进步可能会推动局部麻醉剂市场的发展。
  • 由于该地区进行了大量的外科手术，北美在局部麻醉剂市场上占有最大的份额。
  • 主要参与者包括 Aspen Pharmacare、Fresenius Kabi、诺华、Sagent Pharmaceutical、Pacira Pharmaceutical、Mylan 和 Teva Pharmaceuticals。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章局部麻醉剂市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 局部麻醉剂市场分析工具
    • 波特的分析
    • PESTEL分析

第四章局部麻醉剂市场：按药物分类的预测及趋势分析

  • 细分仪表板
  • 局部麻醉剂市场：2023 年和 2030 年药物变化分析
  • Bupivacaine
  • Ropivacaine
  • Lidocaine
  • Chloroprocaine
  • Prilocaine
  • Benzocaine
  • 其他的

第五章局部麻醉剂市场：按应用估计和趋势分析

  • 细分仪表板
  • 局部麻醉剂市场：2023 年和 2030 年按应用分类的变化分析
  • 注射
  • 表面麻醉

第六章局部麻醉剂市场：区域估算及趋势分析

  • 2023 年及 2030 年按地区分類的局部麻醉剂份额
  • 北美洲
    • 2018-2030 年北美局部麻醉剂估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲局部麻醉剂估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区局部麻醉剂估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲局部麻醉剂估计与预测，2018-2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲局部麻醉剂估计和预测，2018-2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
    • AstraZeneca plc.
    • Novartis AG.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck &Co., Inc.
    • Aspen Pharmacare Holdings Limited
    • Mylan NV
简介目录
Product Code: GVR-2-68038-086-6

Local Anesthesia Drugs Market Growth & Trends:

The global local anesthesia drugs market size is anticipated to reach USD 5.14 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising number of surgical procedures across the globe, including cosmetic surgeries, dental procedures, and plastic surgeries, is driving the growth of local anesthetics.

There has been a considerable increase in the number of surgical procedures requiring post-operative pain relief and this trend is expected to continue throughout the forecast period. Roughly, 65.0% of total surgical procedures require post-operative pain management. This is likely to boost the demand for local anesthesia drugs.

The introduction of new and effective drugs such as levobupivacaine, articaine, and ropivacaine is also driving the growth of the local anesthesia drugs market across the globe. Rising healthcare expenditure in developing countries is expected to result in an increase in the number of surgeries performed in countries such as India, China, and Brazil. This is likely to contribute to market growth in the region.

Local Anesthesia Drugs Market Report Highlights:

  • Lidocaine dominated the market by product as of 2016 owing to its extensive use as a topical and injectable anesthetic
  • By application, the market is bifurcated into injectable and surface anesthetic. The injectable segment is expected to dominate the local anesthesia drugs market during the forecast period owing to extensive usage in different surgical procedures. Advancements in drug delivery systems are expected to drive the market for surface anesthetics over the forecast period
  • North America held the largest share in the market for local anesthesia drugs owing to a significant number of surgical procedures performed in the region
  • Some of the key players are Aspen Pharmacare; Fresenius Kabi; Novartis, Inc.; Sagent Pharmaceutical; Pacira Pharmaceutical; Mylan; and Teva Pharmaceuticals.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Local Anesthesia Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Local Anesthesia Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Local Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Local Anesthesia Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Bupivacaine
    • 4.3.1. Bupivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ropivacaine
    • 4.4.1. Ropivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lidocaine
    • 4.5.1. Lidocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Chloroprocaine
    • 4.6.1. Chloroprocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Prilocaine
    • 4.7.1. Prilocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Benzocaine
    • 4.8.1. Benzocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Local Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Local Anesthesia Drugs Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Injectable
    • 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Surface Anesthetic
    • 5.4.1. Surface Anesthetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Local Anesthesia Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Local Anesthesia Drugs Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Local Anesthesia Drugs and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Johnson & Johnson Services, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. AstraZeneca plc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Novartis AG.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. GlaxoSmithKline plc
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Sanofi S.A.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Aspen Pharmacare Holdings Limited
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Mylan N.V.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives